394 related articles for article (PubMed ID: 30294275)
1. Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis.
Manova M; Savova A; Vasileva M; Terezova S; Kamusheva M; Grekova D; Petkova V; Petrova G
Front Pharmacol; 2018; 9():1070. PubMed ID: 30294275
[TBL] [Abstract][Full Text] [Related]
2. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
[TBL] [Abstract][Full Text] [Related]
3. Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel.
Kanters TA; Stevanovic J; Huys I; Vulto AG; Simoens S
Front Pharmacol; 2017; 8():322. PubMed ID: 28620302
[No Abstract] [Full Text] [Related]
4. Drug prices in Latin American countries: the case of rheumatoid arthritis Biosimilars.
Mosegui GBG; Antõnanzas F; de Mello Vianna CM; Rojas P
Adv Rheumatol; 2021 Feb; 61(1):14. PubMed ID: 33632333
[TBL] [Abstract][Full Text] [Related]
5. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.
Car E; Vulto AG; Houdenhoven MV; Huys I; Simoens S
Front Pharmacol; 2023; 14():1151764. PubMed ID: 37153785
[No Abstract] [Full Text] [Related]
6. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
Aladul MI; Fitzpatrick RW; Chapman SR
BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626
[TBL] [Abstract][Full Text] [Related]
7. Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012-19.
Chen HH; Yemeke T; Ozawa S
PLoS One; 2024; 19(6):e0304851. PubMed ID: 38843282
[TBL] [Abstract][Full Text] [Related]
8. The Expiry of Humira
Moorkens E; Godman B; Huys I; Hoxha I; Malaj A; Keuerleber S; Stockinger S; Mörtenhuber S; Dimitrova M; Tachkov K; Vončina L; Palčevski VV; Achniotou G; Slabý J; Popelková L; Kohoutová K; Bartels D; Laius O; Martikainen JE; Selke GW; Kourafalos V; Magnússon E; Einarsdóttir R; Adams R; Joppi R; Allocati E; Jakupi A; Viksna A; Greičiūtė-Kuprijanov I; Vella Bonanno P; Suttorp V; Melien Ø; Plisko R; Mardare I; Meshkov D; Novakovic T; Fürst J; Zara C; Marković-Peković V; Grubiša N; Befrits G; Puckett R; Vulto AG
Front Pharmacol; 2020; 11():591134. PubMed ID: 33519450
[No Abstract] [Full Text] [Related]
9. Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries.
Kawalec P; Stawowczyk E; Tesar T; Skoupa J; Turcu-Stiolica A; Dimitrova M; Petrova GI; Rugaja Z; Männik A; Harsanyi A; Draganic P
Front Pharmacol; 2017; 8():288. PubMed ID: 28642700
[No Abstract] [Full Text] [Related]
10. Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria.
Tachkov K; Mitkova Z; Boyadzieva V; Petrova G
Pharmaceuticals (Basel); 2021 Jan; 14(1):. PubMed ID: 33466766
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab-Polish Experiences.
Barszczewska O; Piechota A
Int J Environ Res Public Health; 2021 Jun; 18(13):. PubMed ID: 34209612
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Cardiovascular Medicines Prices in Four European Countries.
Mitkova Z; Vasileva M; Savova A; Manova M; Terezova S; Petrova G
Front Public Health; 2020; 8():433. PubMed ID: 32974262
[TBL] [Abstract][Full Text] [Related]
13. A Cross-National Comparison of Biosimilars Pricing in Argentina, Australia, Brazil, and Italy.
da Silva Machado FL; Cañás M; Urtasun MA; Marín GH; Albuquerque FC; Pont L; Convertino I; Bonaso M; Tuccori M; Kirchmayer U; Lopes LC
Ther Innov Regul Sci; 2024 May; 58(3):549-556. PubMed ID: 38436905
[TBL] [Abstract][Full Text] [Related]
14. Do generics offer significant savings to the UK National Health Service?
Kanavos P
Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
[TBL] [Abstract][Full Text] [Related]
15. Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis.
Bocquet F; Paubel P; Fusier I; Cordonnier AL; Le Pen C; Sinègre M
Appl Health Econ Health Policy; 2014 Jun; 12(3):315-26. PubMed ID: 24578185
[TBL] [Abstract][Full Text] [Related]
16. Comparative price analysis of biological medicines: disparities generated by different pricing policies.
Pontes MA; Ribeiro AA; Albuquerque FC; Leite Cotenzini SN
Front Pharmacol; 2023; 14():1256542. PubMed ID: 38273835
[No Abstract] [Full Text] [Related]
17. Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience.
Bocquet F; Paubel P; Fusier I; Cordonnier AL; Sinègre M; Le Pen C
Appl Health Econ Health Policy; 2015 Feb; 13(1):47-59. PubMed ID: 25189295
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria.
Tachkov K; Mitkova Z; Milushewa P; Petrova G
Healthcare (Basel); 2021 Jun; 9(6):. PubMed ID: 34207707
[TBL] [Abstract][Full Text] [Related]
19. Trends in list prices, net prices, and discounts of self-administered injectable tumor necrosis factor inhibitors.
San-Juan-Rodriguez A; Piro VM; Good CB; Gellad WF; Hernandez I
J Manag Care Spec Pharm; 2021 Jan; 27(1):112-117. PubMed ID: 33377437
[No Abstract] [Full Text] [Related]
20. Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings?
Beck M; Michel B; Rybarczyk-Vigouret MC; Sordet C; Sibilia J; Velten M
Eur J Hosp Pharm; 2017 Mar; 24(2):85-90. PubMed ID: 31156910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
